Trial Profile

Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 10 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

18 Oct 2017 Results assessing the maximum tolerated dose (MTD), recommended phase II dose of afatinib in elderly patients with advanced NSCLC harboring EGFR mutations, were presented at the 18th World Conference on Lung Cancer.
31 Oct 2016 Status changed from active, no longer recruiting to completed.
28 Aug 2016 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com